Literature DB >> 28064072

Long-term outcome of breast cancer patients with pathologic N3a lymph node stage.

Antonino Grassadonia1, Patrizia Vici2, Teresa Gamucci3, Luca Moscetti4, Laura Pizzuti2, Lucia Mentuccia3, Laura Iezzi5, Maria Teresa Scognamiglio5, Marinella Zilli5, Jamara Giampietro5, Vincenzo Graziano5, Clara Natoli6, Nicola Tinari6.   

Abstract

PURPOSE: To evaluate factors influencing the long-term outcome of patients presenting with 10 or more metastatic axillary lymph nodes (pN3a) after surgery for primary breast cancer.
METHOD: Between January 1990 and December 2015, a total of 130 patients with pN3a breast cancer at surgery were identified in our Institutions and included in the study. Twenty-nine of them (22.3%) received neoadjuvant chemotherapy. The Multivariate Cox proportional hazards model was used to determine independent prognostic factors associated with DFS and OS.
RESULTS: After a median follow-up of 6.4 years (range 0.87-25 years), 2 patients had a local relapse, 59 distant metastases (1 with local relapse) and 52 patients died. The 5-year DFS and OS rates were 61.8% and 71.5%, respectively. At multivariate analysis, pN3a stage after neoadjuvant chemotherapy (ypN3a) was significantly associated with increased risk of recurrence (HR 1.92, p = 0.02) and death (HR 2.05, p = 0.029). Absence of progesterone receptor (PR) expression was the most important tumor characteristic associated with poor prognosis, both in terms of recurrence (HR 2.55, p < 0.001) and death (HR 2.23, p = 0.019). High levels of Ki-67 index (≥20%) were significantly associated with a shorter OS (HR 2.03, p = 0.027), but not with DFS.
CONCLUSIONS: The results of this study indicate that ypN3a stage, lack of expression of PR, and Ki-67 ≥ 20% negatively affect long-term outcome of patients with pN3a breast cancer.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Breast cancer; Ki-67; Progesterone Receptor; Prognosis; Stage pN3a

Mesh:

Substances:

Year:  2017        PMID: 28064072     DOI: 10.1016/j.breast.2016.12.018

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  2 in total

1.  Clinical Outcomes of N3 Breast Cancer: A Real-World Study of a Single Institution and the US Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Xiang Ai; Xin Liao; Junyan Li; Peng Tang; Jun Jiang
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

2.  Nontherapeutic Risk Factors of Different Grouped Stage IIIC Breast Cancer Patients' Mortality: A Study of the US Surveillance, Epidemiology, and End Results Database.

Authors:  Yue Qiu; Hongye Chen; Yongjing Dai; Baoshi Bao; Lin Tian; Yuhui Chen
Journal:  Breast J       Date:  2022-08-30       Impact factor: 2.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.